Search
Biotech CEO Sisterhood: Avidity Biosciences' CEO Sarah Boyce discusses a leader's responsibility to address dysfunction and the importance of corporate culture
Interviewed by Sisterhood editorial board member Sheila Gujrathi, Sarah Boyce describes how to recognize dysfunction and the importance...
Feb 4
Avidity Biosciences' CEO Sarah Boyce discusses the company's Exon 44 skipping data in DMD that showed a 25% increase in dystrophin production
She describes how this PMO based antibody oligonucleotide conjugate works and why she believes the result validates her belief that...
Aug 13, 2024
Antibody oligonucleotide conjugates as an RNA strategy with the CEO of Avidity Biosciences
Sarah Boyce explains the rationale for using AOCs against muscle disorders like Myotonic dystrophy type 1 and DMD.
Nov 1, 2023
.png){kind=logo}
